LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_007294.4:c.4253T>C
BRCA1
· NP_009225.1:p.(Leu1418Ser)
· NM_007294.4
GRCh37: chr17:41234525 A>G
·
GRCh38: chr17:43082508 A>G
Gene:
BRCA1
Transcript:
NM_007294.4
Final call
VUS
BP4 supporting
Variant details
Gene
BRCA1
Transcript
NM_007294.4
Protein
NP_009225.1:p.(Leu1418Ser)
gnomAD AF
6.195057583060235e-07 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
VUS: BP4 supporting is met because BayesDel 0.0666657 and SpliceAI 0.01 satisfy the ENIGMA no-impact thresholds.
Final determination:
Under ENIGMA BRCA1 VCEP Table 3, one Supporting benign criterion alone does not satisfy any benign or likely benign rule, while no pathogenic combination is met; the resulting call is VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: c.4253T>C is a missense variant, whereas the ENIGMA PVS1 rule applies to null variants such as nonsense, frameshift, canonical splice-site, initiation-codon, or exon-loss variants. |
cspec
vcep_specifications_table4_v1_2_2024_11_18
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
|
| PS1 | Not met | Not met: SpliceAI is 0.01, but no previously classified pathogenic variant producing the same Leu1418Ser substitution was identified. |
cspec
clinvar
spliceai
|
| PS2 | N/A | Not applicable: the ENIGMA VCEP says PS2 must not be used because de novo occurrences lack calibrated predictive value for BRCA1/2-related cancers. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PS3 | Not assessed | Not assessed: ENIGMA Table 9 and ST4 contain no exact c.4253T>C functional-assay entry or calibrated PS3 assignment. |
cspec
vcep_specifications_table9_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_humu_40_1557_s001
|
| PS4 | Not assessed | Not assessed: no verified case-control counts, odds ratio, p-value, or confidence interval are available for c.4253T>C. |
cspec
PMID:23788249
|
| PM1 | N/A | Not applicable: residue 1418 lies in the 1391-1424 coiled-coil domain, but ENIGMA explicitly marks PM1 not applicable and redirects this evidence to other criteria. |
cspec
vcep_appendices_v1_2_2024_11_18
hotspots
|
| PM2 | Not assessed | Not assessed: the variant is absent from both required non-cancer gnomAD datasets, but the VCEP-required regional average read depth of at least 25 is unavailable. |
cspec
vcep_appendices_v1_2_2024_11_18
gnomad_v2
gnomad_v4
|
| PM3 | Not assessed | Not assessed: no documented Fanconi Anemia phenotype, same-gene co-occurring pathogenic/likely pathogenic variant, or trans phase is available to meet the VCEP PM3 pathway. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PM4 | N/A | Not applicable: Leu1418Ser is a single-residue substitution and causes no protein-length change from an in-frame indel or stop-loss variant. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PM5 | N/A | Not applicable: PM5 is restricted to genomic PTC changes, whereas c.4253T>C is a missense substitution producing Leu1418Ser. |
cspec
vcep_specifications_table4_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
|
| PM6 | N/A | Not applicable: the ENIGMA VCEP says PM6 must not be used because unconfirmed de novo occurrences lack calibrated predictive value for BRCA1/2-related cancers. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| PP1 | Not assessed | Not assessed: no quantitative co-segregation LR for multiple affected relatives is available; the only located LR is clinical-history LR 1.47600089290012, not PP1 evidence. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_pmid_31853058_brca1_clinical_history_lr
PMID:31853058
|
| PP2 | N/A | Not applicable: ENIGMA states that missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2. |
cspec
|
| PP3 | Not met | Not met: BayesDel 0.0666657 is below the VCEP PP3 threshold of ≥0.28 and SpliceAI 0.01 is below its ≥0.2 splice threshold. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
bayesdel
spliceai
|
| PP4 | N/A | Not applicable: Li et al. clinical-history LR 1.47600089290012 is below the PP4 supporting threshold of 2.08. |
cspec
vcep_pmid_31853058_brca1_clinical_history_lr
PMID:31853058
|
| PP5 | N/A | Not applicable: the ENIGMA BRCA1 VCEP explicitly states that PP5 should not be used. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| BA1 | Not met | Not met: the variant is absent from the specified non-cancer gnomAD datasets and the available all-comers AF is 6.19506e-07, far below the 0.001 BA1 threshold. |
cspec
vcep_appendices_v1_2_2024_11_18
gnomad_v2
gnomad_v4
|
| BS1 | Not met | Not met: the variant is absent from the specified non-cancer gnomAD datasets and the available all-comers AF 6.19506e-07 is below the 0.00002 BS1 Supporting threshold. |
cspec
vcep_appendices_v1_2_2024_11_18
gnomad_v2
gnomad_v4
|
| BS2 | Not assessed | Not assessed: no qualifying healthy-adult clinical observation or same-gene pathogenic co-occurrence is available, and gnomAD frequency data cannot supply BS2 points. |
cspec
vcep_appendices_v1_2_2024_11_18
gnomad_v4
|
| BS3 | Not assessed | Not assessed: ENIGMA Table 9 and ST4 contain no exact c.4253T>C functional-assay entry or calibrated BS3 assignment. |
cspec
vcep_specifications_table9_v1_2_2024_11_18
vcep_supplementarytables_v1_2_2024_11_18
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
vcep_humu_40_1557_s001
|
| BS4 | Not assessed | Not assessed: no quantitative non-segregation LR or affected-relative genotype data is available to meet the ENIGMA BS4 thresholds. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| BP1 | Not met | Not met: SpliceAI is 0.01, but Leu1418 lies inside the VCEP coiled-coil domain spanning residues 1391-1424. |
cspec
vcep_appendices_v1_2_2024_11_18
spliceai
|
| BP2 | N/A | Not applicable: ENIGMA explicitly says BP2 is not to be used and is applied only in the context of BS2. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| BP3 | N/A | Not applicable: BP3 requires an in-frame deletion or insertion in a repetitive region, but c.4253T>C is a missense substitution. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| BP4 | Met | Met at Supporting: BayesDel 0.0666657 is ≤0.15 and SpliceAI max delta 0.01 is ≤0.1 for this coiled-coil missense variant. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
bayesdel
spliceai
|
| BP5 | N/A | Not applicable: Li et al. clinical-history LR 1.47600089290012 is above the BP5 supporting threshold of 0.48. |
cspec
vcep_pmid_31853058_brca1_clinical_history_lr
PMID:31853058
|
| BP6 | N/A | Not applicable: the ENIGMA BRCA1 VCEP explicitly marks BP6 as not for use. |
cspec
vcep_specifications_v1_2_2024_11_18
|
| BP7 | N/A | Not applicable: the VCEP BP7 paths cover silent or intronic variants, whereas this variant is missense. |
cspec
vcep_specifications_v1_2_2024_11_18
vcep_appendices_v1_2_2024_11_18
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.